Repligen Co. (NASDAQ:RGEN) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 2.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 135,585 shares of the biotechnology company’s stock after selling 3,092 shares during the period. Geneva Capital Management LLC’s holdings in Repligen were worth $19,516,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in RGEN. Champlain Investment Partners LLC raised its stake in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the period. Raymond James Financial Inc. acquired a new position in Repligen in the 4th quarter valued at $52,492,000. Allspring Global Investments Holdings LLC raised its stake in Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after purchasing an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. raised its stake in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in Repligen by 421.9% in the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after purchasing an additional 102,100 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Stock Performance

NASDAQ RGEN opened at $157.67 on Thursday. The stock has a market cap of $8.83 billion, a PE ratio of -309.16, a P/E/G ratio of 4.54 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $203.13. The stock has a fifty day simple moving average of $156.74 and a 200-day simple moving average of $148.54.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Equities analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.